Related Experiment Video
Updated: Jul 8, 2026
03:50
Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
Published on: August 18, 2023
Constipation in cancer patients on morphine
Joanne Droney1, Joy Ross, Sophy Gretton
1Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK. jodroney@hotmail.com
Summary
Constipation significantly impacts cancer patients on oral morphine, with 72% affected. Current laxative treatments are often inadequate, highlighting a need for personalized management strategies for cancer pain patients.
Area of Science:
- Oncology
- Palliative Care
- Gastroenterology
Background:
- Constipation is a prevalent and significant issue for cancer patients receiving oral morphine for pain management.
- Effective management of opioid-induced constipation (OIC) is crucial for maintaining patient quality of life and treatment adherence.
Purpose of the Study:
- To quantify the prevalence of constipation in cancer patients treated with oral morphine.
- To evaluate current constipation treatment strategies and laxative use within this patient group.
- To investigate inter-individual variations in susceptibility to constipation and response to laxative therapy.
Main Methods:
- An observational study involving 274 cancer patients on oral morphine was conducted at a tertiary cancer hospital.
- Constipation severity was assessed using a four-point subjective scale.
- Laxative use was documented, and laxative dose groups (LDGs) were established to analyze treatment intensity.
Main Results:
- A high prevalence of constipation was observed, affecting 72% of the study cohort.
- Constipation management was found to be inadequate in 89% of affected patients, with many on insufficient laxative therapy.
- Significant inter-individual variation in constipation experience and laxative response was noted, but no specific factors accounted for this variability.
Conclusions:
- Constipation is a widespread problem among cancer patients using oral morphine, underscoring the need for improved clinical management.
- Current treatment approaches for opioid-induced constipation are frequently inadequate, necessitating a shift towards individualized laxative titration based on patient needs.
Related Concept Videos
01:17Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:25Assessment of the Rectum and Anus
Evaluating the rectum and anus plays a crucial role in conducting a thorough physical examination of the gastrointestinal system. Although it may be uncomfortable and often embarrassing for the patient, it holds immense diagnostic value, particularly in detecting gastrointestinal diseases and abnormalities. This guide will explain how to perform this assessment using inspection and palpation methods.
Rectal Inspection
Begin by inspecting the perianal and anal areas for color, texture, rashes,...
Rectal Inspection
Begin by inspecting the perianal and anal areas for color, texture, rashes,...
01:20Drugs Affecting GI Tract Motility: Other Laxatives
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
01:22Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...